The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Expanding patient access to clinical trials after CAR-T failure in R/R LBCL
Dai Chihara, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses factors affecting clinical trial access after CAR-T failure in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Chihara highlights that approximately two-thirds of these patients are ineligible due to severe cytopenias and suggests that the field needs to re-evaluate safe cutoffs for eligibility criteria to ensure timely access to new treatments. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
